Lemborexant for the Treatment of Insomnia in Patients From China: Four Case Studies

伦博雷生治疗中国失眠患者的病例报告:四例病例研究

阅读:1

Abstract

Lemborexant is a competitive antagonist of dual orexin receptors indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance that occur at least three nights per week for ≥3 months, although there is adequate opportunity for sleep. There has been no published study of its efficacy and safety in treating patients from China with insomnia. In this case report, we present four adult patients from China with insomnia who were successfully treated with add-on lemborexant or switched from benzodiazepines or Z-drugs to lemborexant. None of the four patients experienced any discomforts related to lemborexant use. In conclusion, lemborexant treatment was effective and safe in treating the four patients from China with insomnia in this case report, and more studies are warranted to further assess the efficacy and safety of lemborexant in treating patients from China with insomnia.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。